Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | TK2 | O00142 | 1/20 | 0.59 |
| ▸ | TYMS | P04818 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21316832 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL887786 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL5982137 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2922785 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL13030268 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL887788 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL535679 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL535680 | 1.00 | TK1 (0.77) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL15457036 | 0.90 | TK1 (0.75) | TK1CYP1A2CYP3A4TSHRBLM | |
| SCHEMBL12883747 | 0.90 | TK1 (0.75) | TK1CYP1A2CYP3A4TSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385090-B2 | Nucleotide derivative or salt thereof, nucleotide-derived 5′-phosphate ester or salt thereof, nucleotide-derived 3′-phosphoramidite compound or salt thereof, and polynucleotide | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2019-08-20 | — | — | US | disclosed |
| EP-2891714-B1 | METHOD FOR ANALYZING TARGET NUCLEIC ACID, KIT, AND ANALYZER | DNAFORM KK (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-9499576-B2 | Compound, nucleic, acid, method for producing nucleic acid, and kit for producing nucleic acid | RIKEN (JP) | 2016-11-22 | — | — | US | disclosed |
| US-9499576-B2 | Compound, nucleic, acid, method for producing nucleic acid, and kit for producing nucleic acid | RIKEN (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20160311845-A1 | NUCLEOTIDE DERIVATIVE OR SALT THEREOF, NUCLEOTIDE-DERIVED 5'-PHOSPHATE ESTER OR SALT THEREOF, NUCLEOTIDE-DERIVED 3'-PHOSPHORAMIDITE COMPOUND OR SALT THEREOF, AND POLYNUCLEOTIDE | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20160311845-A1 | NUCLEOTIDE DERIVATIVE OR SALT THEREOF, NUCLEOTIDE-DERIVED 5'-PHOSPHATE ESTER OR SALT THEREOF, NUCLEOTIDE-DERIVED 3'-PHOSPHORAMIDITE COMPOUND OR SALT THEREOF, AND POLYNUCLEOTIDE | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2016-10-27 | — | — | US | disclosed |
| US-9382286-B2 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150203902-A1 | NUCLEIC ACID PROBE, METHOD FOR DESIGNING NUCLEIC ACID PROBE, AND METHOD FOR DETECTING TARGET SEQUENCE | KABUSHIKI KAISHA DNAFORM (JP) | 2015-07-23 | — | — | US | disclosed |
| EP-2891714-A1 | METHOD FOR ANALYZING TARGET NUCLEIC ACID, KIT, AND ANALYZER | Kabushiki Kaisha Dnaform (JP) | 2015-07-08 | — | — | EP | disclosed |
| US-20150152496-A1 | METHOD FOR ANALYZING TARGET NUCLEIC ACID, KIT, AND ANALYZER | KABUSHIKI KAISHA DNAFORM (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2660246-A1 | COMPOUND, NUCLEIC ACID, METHOD FOR PRODUCING NUCLEIC ACID, AND KIT FOR PRODUCING NUCLEIC ACID | Riken (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-20130289263-A1 | COMPOUND, NUCLEIC ACID, METHOD FOR PRODUCING NUCLEIC ACID, AND KIT FOR PRODUCING NUCLEIC ACID | RIKEN (JP) | 2013-10-31 | — | — | US | disclosed |
| US-20130289263-A1 | COMPOUND, NUCLEIC ACID, METHOD FOR PRODUCING NUCLEIC ACID, AND KIT FOR PRODUCING NUCLEIC ACID | RIKEN (JP) | 2013-10-31 | — | — | US | disclosed |
| US-8383792-B2 | Compound having structure derived from mononucleoside or mononucleotide, nucleic acid, labeling substance, and method and kit for detection of nucleic acid | RIKEN (JP) | 2013-02-26 | — | — | US | disclosed |
| US-8383792-B2 | Compound having structure derived from mononucleoside or mononucleotide, nucleic acid, labeling substance, and method and kit for detection of nucleic acid | RIKEN (JP) | 2013-02-26 | — | — | US | disclosed |
| US-8067162-B2 | Replication; hybridization; kits | RIKEN (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20100168052-A1 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation | PHARMASSET, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100092971-A1 | COMPOUND HAVING STRUCTURE DERIVED FROM MONONUCLEOSIDE OR MONONUCLEOTIDE, NUCLEIC ACID, LABELING SUBSTANCE, AND METHOD AND KIT FOR DETECTION OF NUCLEIC ACID | RIKEN (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20080227104-A1 | Replication; hybridization; kits | RIKEN (JP) | 2008-09-18 | — | — | US | disclosed |
| EP-1970453-A2 | Primer, primer set, and nucleic acid amplification method and mutation detection method using the same | Riken (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092971-A1 | COMPOUND HAVING STRUCTURE DERIVED FROM MONONUCLEOSIDE OR MONONUCLEOTIDE, NUCLEIC ACID, LABELING SUBSTANCE, AND METHOD AND KIT FOR DETECTION OF NUCLEIC ACID | NME1, NGLY1, DNTT | TK1 21/4885CYP1A2 4856/4885CYP3A4 4806/4885 |
| US-20080227104-A1 | Replication; hybridization; kits | PCNA, POLL, RNGTT | TK1 300/4885CYP1A2 4851/4885CYP3A4 4220/4885 |
| US-20100168052-A1 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation | UMPS, ENTPD5, TK1 | TK1 3/4885CYP1A2 2865/4885CYP3A4 1310/4885 |
| US-20160311845-A1 | NUCLEOTIDE DERIVATIVE OR SALT THEREOF, NUCLEOTIDE-DERIVED 5'-PHOSPHATE ESTER OR SALT THEREOF, NUCLEOTIDE-DERIVED 3'-PHOSPHORAMIDITE COMPOUND OR SALT THEREOF, AND POLYNUCLEOTIDE | NT5C3B, PNP, NUDT1 | TK1 32/4885CYP1A2 4511/4885CYP3A4 4502/4885 |
| US-10385090-B2 | Nucleotide derivative or salt thereof, nucleotide-derived 5′-phosphate ester or salt thereof, nucleotide-derived 3′-phosphoramidite compound or salt thereof, and polynucleotide | SLC34A1, SLC34A2, SLC34A3 | TK1 18/4885CYP1A2 4812/4885CYP3A4 4610/4885 |
| US-20130289263-A1 | COMPOUND, NUCLEIC ACID, METHOD FOR PRODUCING NUCLEIC ACID, AND KIT FOR PRODUCING NUCLEIC ACID | DNTT, POLRMT, NSUN2 | TK1 248/4885CYP1A2 4607/4885CYP3A4 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.